Нидерланды - голландский - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

teva nederland b.v. swensweg 5 2031 ga haarlem - amfotericine b 5 mg/ml - concentraat voor oplossing voor infusie - l-alpha-dimyristoylphosphatidylcholine (ri) ; l-alpha-dimyristoylphosphatidylglycerol ( as sodium ammonium salt) (ri) ; natriumchloride ; stikstof (head space) (e 941) ; water, gezuiverd, - amphotericin b

Нидерланды - голландский - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

substipharm - ivermectine - tablet - butylhydroxyanisol (e 320) ; cellulose, microkristallijn (e 460) ; magnesiumstearaat (e 470b) ; zetmeel, gepregelatineerd, - ivermectin

Нидерланды - голландский - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

substipharm 24 rue erlanger 75016 parijs (frankrijk) - ivermectine - tablet - butylhydroxyanisol (e 320) ; cellulose, microkristallijn (e 460) ; magnesiumstearaat (e 470b) ; zetmeel, gepregelatineerd, - ivermectin

Нидерланды - голландский - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

galenicum derma, s.l. ctra n-1, km 36 28750 san agustÍn del guadalix (spanje) - ivermectine 3 mg/stuk - tablet - butylhydroxyanisol (e 320) ; cellulose, microkristallijn (e 460(i)) ; magnesiumstearaat (e 470b) ; maÏszetmeel, gepregelatineerd, butylhydroxyanisol (e 320) ; cellulose, microkristallijn (e 460) ; magnesiumstearaat (e 470b) ; maÏszetmeel, gepregelatineerd

Нидерланды - голландский - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

ivermectine 3 mg/stuk - tablet - butylhydroxyanisol (e 320) ; cellulose, microkristallijn (e 460(i)) ; citroenzuur 0-water (e 330) ; magnesiumstearaat (e 470b) ; maÏszetmeel, gepregelatineerd, butylhydroxyanisol (e 320) ; cellulose, microkristallijn (e 460) ; citroenzuur 0-water (e 330) ; magnesiumstearaat (e 470b) ; maÏszetmeel, gepregelatineerd

Нидерланды - голландский - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

ivermectine 3 mg/stuk - tablet - butylhydroxyanisol (e 320) ; cellulose, microkristallijn (e 460(i)) ; citroenzuur 0-water (e 330) ; magnesiumstearaat (e 470b) ; maÏszetmeel, gepregelatineerd, butylhydroxyanisol (e 320) ; cellulose, microkristallijn (e 460) ; citroenzuur 0-water (e 330) ; magnesiumstearaat (e 470b) ; maÏszetmeel, gepregelatineerd

Европейский союз - голландский - EMA (European Medicines Agency)

kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - antineoplastische middelen - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.

Европейский союз - голландский - EMA (European Medicines Agency)

kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - lymfoom, mantel-cel - antineoplastische middelen - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).

Европейский союз - голландский - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - antineoplastische middelen - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Европейский союз - голландский - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - antineoplastische middelen - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.